Ocular Therapeutix (OCUL) — Research Snapshot (as of 2026-10-30)

Company context: A biopharmaceutical company developing and commercializing retinal-eye therapies using its proprietary ELUTYX bioresorbable hydrogel platform; lead asset AXPAXLI (OTX-TKI), an axitinib intravitreal hydrogel, is in Phase 3 for wet AMD and non-proliferative diabetic retinopathy (NPDR) [3][10][18]. Market cap is listed at ~$1.60B on your system (2026-10-29), though CatalystAlert reports ~$2.2B (2026-10-27) — a discrepancy worth flagging rather than reconciling [1]. The stock closed at $7.31 on 2026-10-29 [15].

Key Recent Catalysts (July–October 2026)